Author, date, study type, level of evidence, Heyland score

Patient group

Complications reported

Nutritional outcomes

Dann et al. 2015

Retrospective Cohort Study

CEBM Level 4

Heyland Score (/11)

Total = 345

J-tube = 186 (53.9%)

No J-tube = 159 (46.1%)

Any Complication:

57.5% JT vs. 45.9% No JT*

Major Complication^{^}:

26.3% JT vs. 23.3% No JT

Infectious Complication:

38.7% JT vs. 25.8% No JT*

Surgical Site Infection:

15.1% JT vs. 8.2% No JT

Deep Intra-Abdominal Infection:

12.9% JT vs. 5.7% No JT*

Reoperation: 13.4% JT vs. 8.8% No JT

30-Day Readmission:

15.6% JT vs. 17.0% No JT

Length of Stay (days):

14.4 (±9.9) JT vs. 11.4 (±8.8)*

Adjuvant Chemotherapy:

55.9% JT vs. 56.8% No JT

Adjuvant Radiation Therapy:

37.7% JT vs. 33.8% No JT

Any Adjuvant Therapy:

56.5% JT vs. 56.8% No JT

Heylen et al. 1987

Prospective Randomised Control Trial

CEBM Level 2

Heyland Score (/11): 5

Total = 20

J-tube = 10 (50%)

TPN = 10 (50%)

JT:

Catheter Complications: 0%

Superficial Wound Abscess: 10%

No Other Complications Reported

TPN:

Thrombosis: 10%

Superficial Wound Abscess: 10%

Deep Abscess: 10%

No Other Complications Reported

Actual Calorie Intake vs. Prescribed Amount:

JT: 83% of Intended Target

TPN: Identical to Prescribed Amount

Total Caloric Intake**:

JT: 11,690 kcal/pt/8 days vs.

TPN: 12,200 kcal/pt/8 days

Weight Loss:

JT: 3.7 kg vs. TPN: 5.1 kg*

Mid-Upper Arm Circumference

JT: −1.6 cm vs. TPN: −0.4 cm

Blood Biochemistry at Day 8***:

No Significant Difference between JT and TPN

Patel et al. 2013

Retrospective Cohort Study

CEBM Level 4

Heyland Score (/11): 5

Total = 46

J-tube: 32 (69.6%)

No J-tube: 14 (30.4%)

Any Complication:

53% JT vs. 43% No JT

Infectious Complication:

34% JT vs. 14% No JT

Major Complication^:

6% JT vs. 0% No JT

Reoperation: 3% JT vs. 0% No JT

Bleeding Requiring Packed RBC Transfusion:

0% JT and No JT

Anastomotic Leak: 0% JT and 0% No JT

30-Day Readmission: 22% JT vs. 21% No JT

Length of Stay (days):

14 (8 - 30)^a JT vs. 10 (5 - 15)^a No JT*

Albumin Pre-Operative:

3.4 (1.8 - 4.2)^a JT vs. 3.2 (2.1 - 4.1)^a No JT

Albumin 30-Day:

2.9 (1.12 - 3.8)^a JT vs. 2.7 (2.0 - 3.3)^a No JT

Albumin 60-Day:

3.2 (1.3 - 4.4)^a JT vs. 2.7 (2.0 - 3.7)^a No JT

Albumin 90-Day:

3.5 (1.9 - 4.5)^a JT vs. 3.2 (2.7 - 3.6)^a No JT

Received Adjuvant Therapy Post-Op:

66% JT vs. 57% No JT